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After the genocide in Rwanda, the country’s healthcare system collapsed. Remarkable gains have since been made
by the state to provide greater clinical service capacity and expand health policies that are grounded on locally
relevant evidence. This commentary explores the challenges faced by Rwanda in building an infrastructure for
clinical trials. Through local examples, we discuss how a clinical trial infrastructure can be constructed by (1)
building educational capacity; (2) encouraging the testing of relevant interventions using appropriate and cost-effective
designs; and, (3) promoting ethical and regulatory standards. The future is bright for clinical research in Rwanda and
with a renewed appetite for locally generated evidence it is necessary that we discuss the challenges and opportunities
in drawing up a clinical trials agenda.
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The depletion of the health system in Rwanda after the
1994 genocide resulted in a paucity of health workers
capable of providing clinical services across the country.
As a result, the priorities for initially rebuilding the
health system have focused on the training of clinicians
and cadres of health service workers, and on supplying
humanitarian aid. More recently, Rwanda has reached a
stabilization period in providing clinical service capacity
and is now expanding priorities to build policies that are
based on locally relevant evidence [1].
In 2014, priorities for building research infrastructure in-
clude the institutionalization of research capacity through
human resource development, investments in program
evaluation, and educational assistance [2,3]. Determining
how future research priorities are developed means making
difficult decisions about where to make research invest-
ments and how to prioritize efforts in research. Should
these investments be in basic sciences, clinical research
or operational evaluations? In the context of limited
resources, there is a consensus that Rwanda should
focus on an evidence-based research agenda to optimize* Correspondence: jcondo@nursph.org
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a robust infrastructure for clinical trials to inform the
scale-up of indigenous research for the most effective in-
terventions. Herein we list the three pressing challenges
related to building a clinical trial infrastructure: (1) build-
ing educational capacity; (2) encouraging the development
of relevant and novel interventions to test; and, (3) pro-
moting ethical and regulatory standards.Building educational capacity
A first step in building clinical trial capacity is providing
educational opportunities for Rwandans and our global
partners. While Rwanda has importantly invested in clinical
staff, focusing on physicians and other grades of front-line
health workers, it has invested much less in the develop-
ment of statistical and methodological health professionals
[3,4]. The most senior health staff in Rwanda are typically
the first cohort of physicians, nurses and other professionals
trained after the genocide. These individuals already hold
senior positions within government and health facilities and
have historically worked in an environment where training
and orientation has focused on improving the efficiency
and quality of clinical service delivery. Although a Master
of Public Health program and a new Doctor of Philosophy
program are available through universities in Rwanda, no
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perience in instructing a course in clinical trial design and
analysis will further improve the training of both masters
and doctoral level public health students. Efforts to rapidly
build clinical trial capacity include partnership with major
universities in the global north, mentorship, training
workshops, and attracting experienced Rwandan faculty;
Rwandans currently working in the university but also
Rwandans outside of the university including those from
the diaspora. There is recognition within the University of
Rwanda and the Ministry of Health that long-term men-
toring between experienced researchers and new investi-
gators is needed to achieve not only basic knowledge of
clinical trial methods but also to assist in problem solving
when trials go awry. Examples are current mentorships
between the Rwanda Biomedical Centre and Stanford
University for HIV trials, a collaboration between the
Rwanda Biomedical Centre and the University of Ottawa
for a dietary supplement trial [5], and ongoing collabora-
tions between the Ministry of Health and Emory University
via the Project San Francisco. These have primarily focused
on HIV projects and will now need to expand to other
disease areas.
Encouraging relevant interventions
It is crucial that we prioritize the testing of relevant and
novel interventions that are in accordance with the bur-
den of disease and needs of the country. While standard
pairwise randomized trials of drugs versus placebos are
unlikely to be among the first trial designs implemented
(owing to their complexity in design and high cost burden),
there is a need for innovative designs to answer locally
relevant questions that compare interventions beyond
simply drug-placebo interactions. For instance, currently
in Rwanda there is a need to evaluate the effectiveness of
many innovative programmatic interventions [6,7]. Exam-
ples of locally relevant clinical trials within Rwanda have
included the ‘Pay for Performance’ economic intervention
for the improvement of the health system [8]; educational
interventions for health behavior change; and task shifting
for voluntary medical male circumcision [9]. As we further
develop capacity for clinical trials, there may be a focus on
different study designs, including cluster designs, im-
plementation science strategies, such as stepped-wedge
designs, and adaptive clinical trials that allow for protocol
changes according to the needs of the local population
and government [10]. Medical guidelines, for example,
HIV treatment guidelines, change rapidly, and trials de-
signed to be locally relevant need to adapt to guideline
changes. For example, the Strategic Timing of Antiretro-
viral Treatment trial [11], a multinational trial evaluating
at what CD4 cell count to start antiretroviral therapy
(≤350 cells mm3 versus immediate therapy), would not be
currently relevant in Rwanda, as guidelines have movedfrom ≤350 in 2008 to ≤500 in 2014 and are likely to move
to immediate treatment at diagnosis by 2015. Further-
more, as Rwanda is experiencing an epidemiological
transition away from infectious diseases, prioritizing of
interventions that address diseases not traditionally deemed
of importance to the region will be increasingly neces-
sary. These include non-communicable diseases, mental
health concerns, and rehabilitation disorders. Treating
non-communicable disease is now a national priority,
but what conditions of non-communicable disease should
be prioritized is unclear [1,12]. For example, simplified
cancer therapies might work for some cancers and not for
others [13]. Preventive strategies for hypertension will
probably yield a greater return on investment than prio-
ritizing treatment of hypertension and its associated
morbidities [14]. Strategies to improve mental health
are probably unique in Rwanda, as the genocide has
resulted in mass mental trauma. What types of evidence
from other settings can be utilized in this setting? Should
rehabilitation interventions target the physical or neuro-
logical disorders that resulted from the genocide? These
questions illustrate how priorities have changed from the
hitherto expected tropical diseases to conditions that are
longer term and may require lifelong assistance.
Promoting ethical standards
Lastly, there is a need for an ethical and regulatory frame-
work for building clinical trial infrastructure. A major con-
cern [9] when determining what types of clinical trial to
embark upon is who sets the agenda of what interventions
should be assessed? There are arguably five major players
interested in conducting clinical trials in Rwanda: the
Rwandan government; academics and their foreign fun-
ders (for example, the US National Institutes of Health);
non-government organizations; and the pharmaceutical
industry. While these are the major actors interested in
clinical trials, the financial sponsors of clinical trials may
have a greater say in what interventions are assessed than
the representative actors. The Rwandan government and
individual academics rarely sponsor clinical trials, owing
to limited access to funds or the restricted mechanisms of
accessing available funding opportunities. It is the respon-
sibility of both Rwandan academics and their collaborators
to ensure that the results of a trial are locally contex-
tualized and support the research agenda set by local
researchers and government officials, to inform policy
and decision makers. Thus far, only trials related to HIV
(vaccines, microbicide and male circumcision) have been
implemented in the country, through partnerships with
industry to provide financial support and products. Simi-
larly, in most academic partnerships, academics from the
West may have opportunities to procure more funding
than their Rwandan counterparts, and so partnerships
may not be always equal. There is a clear need for ethical
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the clinical trials proposed investigate locally relevant
questions that will benefit the population, in addition to
determining issues of design and integrity. In some cases,
protocols of clinical trials presented to institutional review
boards are not systematically followed up with respected
to ethical integrity. For example, the Rwandan institu-
tional board dealing with ethics and human subjects does
not have a data safety and monitoring committee for clin-
ical trials in-country to oversee its regulations and trials
often need to commission other boards for these services.
These are systems that must be strengthened alongside
the growth of educational capacity and the stimulation of
novel interventions, if we are to better address indigenous
health needs in Rwanda.
Conclusions
The future is bright for clinical research in Rwanda, but
immediate challenges remain. A great deal of work has
already been done in improving the healthcare system
and there is an enormous desire for the evaluation of
locally relevant research. However, achieving an environ-
ment that can conduct high-quality research will require
both internal expertise in the country and strong part-
nerships with external experts, as well as opportunities
for growth of local investigators, and the formation of
policies that encourage research while avoiding exploit-
ation. Going forward, building research infrastructure
and capacity will be a key pillar in the development of a
stronger Rwanda.
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